QUOTE AND NEWS
TheStreet.com  Mar 2  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet, Inc., or any of its contributors.  TheStreet Ratings quantitative algorithm evaluates over 4,300 stocks on...
TheStreet.com  Mar 2  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Cracker Barrel was downgraded to hold from buy at Miller Tabak. This was a valuation call, based on a $150 12-month price target, Miller Tabak said. Crane was downgraded to underperform from buy at...
Jutia Group  Feb 19  Comment 
[GlobeNewswire] - AMES, Iowa -- NewLink Genetics Corporation today announced that it had received notification from Merck that the milestone event specified in the license and collaboration agreement between the two companies ... Read more on...
Benzinga  Dec 22  Comment 
NewLink Genetics Corp (NASDAQ: NLNK) and Merck & Co., Inc. (NYSE: MRK) on Monday announced a contract for development of an Ebola vaccine. According to the press release, the Biomedical Advanced Research and Development Authority (BARDA) of...
Benzinga  Dec 11  Comment 
NewLink Genetics Corp (NASDAQ: NLNK) shares fell sharply after a trial of its Ebola vaccine was temporarily halted over safety concerns at a Swiss hospital University of Geneva Hospital halted the Phase I trial "as a precautionary measure"...
Wall Street Journal  Nov 24  Comment 
Merck & Co. has obtained the rights to an experimental Ebola vaccine developed by NewLink Genetics, another sign of the scramble by pharmaceutical companies and other groups to find new ways to combat the deadly viral outbreak centered in West...
Benzinga  Nov 7  Comment 
In a report published Friday, Stifel analyst Stephen Willey reiterated a Buy rating on NewLink Genetics Corp (NASDAQ: NLNK), and raised the price target from $51.00 to $55.00. In the report, Stifel noted, “After recently-signing one of the...




 
TOP CONTRIBUTORS

NewLink Genetics (NASDAQ:NLNK) is a biopharmaceutical which develops drugs to help treat cancer patients.[1] The company focuses on immunotherapy - or treatment by causing the immune system to either act or cease to act. In other words, NewLink Genetics attempts to encourage the patients immune system to combat the cancerous cells rather than attempting to kill the cells directly.[2] NewLink Genetics revenues are dependent on the discovery and FDA approval of its therapies.

Business Overview

For the full year 2010, NewLink generated $2.1M in grant revenue. This was an over 100% increase from the $.9M in 2009. Since the company spends heavily on research and development, it still reported a net loss for 2010 of $16.6M. This compares to a net loss of $10.2M in 2009. [3]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on November 10, 2011. The company offered 6.2M shares each for $7. The company had already planned to sell 5.5M shares. However, since they priced below the $10-$12 range, they increased shares. The deal raised a total of $43M. The lead mangers of the deal were Stifel Financial (SF) and Canaccord Genuity.[4]

Trends & Forces

Dependence on FDA approval

As of its IPO, NewLink did not have any FDA approved drugs. It's quite clear that without a completed drug, the company will be unable to produce substantial operating revenue. As a result, the company's performance is limited to actions from the FDA. Furthermore, since NewLink is in the process of developing new, untested treatments, there is no clear guidance for the likelihood of approval or the likelihood that physicians will adopt new treatments.[5]

  1. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Overview p. 1
  2. American Cancer Society - Find Support and Treatment "Immunotherapy"
  3. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Selected Financial Data p. 51
  4. Renaissance Capital - IPO Home "NewLink Genetics prices IPO at $7, below the range" 11 Nov 2011
  5. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Risk Factors" pp. 11-15
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki